Impact of lipid and ACE inhibitor therapy on cardiovascular disease and metabolic abnormalities in the diabetic and hypertensive patient

Journal of Human Hypertension

Volumn 11, Issue 1, 1997, Pages 9-16

  Sowers, J R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Cardiovascular disease; Diabetes; Lipids

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; OBESITY;

EID: 0030977745     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000394     Document Type: Conference Paper

References (93)

1. Lipid Research Clinics Program. The Lipid Research Clinics Primary Prevention Trials: reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
2. Frick MH et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-1245.
3. Abbott RD et al. High density lipoprotein cholesterol, total cholesterol, and myocardial infarction: The Framingham Study. Arteriosclerosis 1988; 8: 207-211.
4. Flack JM, Sowers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med 1991; 91: 1S-11S.
5. Walsh MF, Dominguez LJ, Sowers JR. Metabolic abnormalities in cardiac ischemia. Cardiol Clinics 1995; 13 (4): 529-538.
6. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis 1978; 31: 201-306.
7. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1993; 13 (Suppl 1): 2-12.
8. Sowers JR et al. Diabetes mellitus and hypertension: the double whammy. Cardiovasc Risk Factors 1993; 3: 164-169.
9. The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23: 145-158.
10. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: An update. Hypertension 1995; 26 (Part 1): 869-879.
11. Sowers JR, Epstein. Diabetes mellitus and hypertension, emerging therapeutic perspectives. Cardiovasc Drug Rev 1995; 13 (2): 149-210.
12. Bakris GL et al. Analogy between endothelial/ mesangial cell and endothelial/vascular smooth muscle cell interactions. In: Sowers JR (ed), Contemporary Endocrinology: Endocrinology of the Vasculature, Humana Press, Totowa, NJ, 1996, pp 341-355.
13. Laakso M, Barrett-Connor E. Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis 1995; 9: 665-672.
14. Al Muhtaseb N et al. Lipoproteins and apolipoproteins in young nonobese Arab women with NIDDM treated with insulin. Diabetes Care 1989; 12: 325-331.
15. Hunt SC et al. Genetic heritability and common environmental components of resting and stressed blood pressures, lipids, and body mass index in Utah pedigrees and twins. Am J Epidemiol 1989; 129: 625-638.
16. Selby JV et al. Concordance for dyslipidemic hypertension in male twins. JAMA 1991; 265Z: 2078-2084.
17. Williams RR et al. Are there interactions and relations between genetic and environmental factors predisposing to high blood pressure? Hypertension 1991; 18 (Suppl 1): I29-I37.
18. Johansen K et al. Coronary artery disease, HDL cholesterol, and insulin-gene flanking sequences. Diabetic Med 1989; 6: 429-433.
19. Nishina PM et al. Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 1992; 89: 708-712.
20. Amos CI et al. Polymorphism in the 5′ flanking region of the insulin gene and its potential relation to cardiovascular disease risk: observations in a biracial community. The Bogalusa Heart Study. Atherosclerosis 1989; 79: 51-57.
21. Sowers JR. Relationships between hypertension and subtle and overt abnormalities of carbohydrate metabolism. J Am Soc Nephrol 1990; 1: 539-547.
22. Sowers JR. Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension, and accelerated atherosclerosis. J Clin Pharm 1992; 32: 529-535.
23. Sowers JR, Standley PR, Ram JL, Jacober S. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenes of hypertension and atherosclerosis. Am J Hypers 1993; 6: 260S-270S.
24. Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Metab 1994; 123: 647-652.
25. Carlsson LA, Aberg H, Serum triglyceride - an independent risk factor for myocardial infarction but not for angina pectoris. NEJM 1985; 312: 1127-1132.
26. Zavaroni I et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320: 702-706.
27. Jensen M et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989; 33: 1158-1173.
28. Randle PJ, Priestman DA, Misby SC, Halsall A. Glucose fatty acid interactions and the regulation of glucose disposal (review). J Cell Biochem 1994; 55: 1-11.
29. Sundell IB et al. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 1989; 80: 9-16.
30. Ramirez LC et al. Lipoprotein (a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med 1992; 117: 42-47.
31. Scanu AM. Lipoprotein (a): a genetic risk factor for premature coronary heart disease. JAMA 1991; 267: 3326-3329.
32. Valentine RJ et al. Lp(a) lipoprotein is an independent discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994; 154: 801-806.
33. Schwartz CJ et al. Pathogenesis of the atherosclerotic lesion: implications for diabetes mellitus. Diabetes Care 1992; 15 (9): 1156-1167.
34. Schwartz CJ et al. Pathogenesis of the atherosclerotic lesion: implications for diabetes mellitus. Diabetes Care 1992; 15: 1156-1167.
35. Lyons TJ, Lopes-Virella MF, Baystle JW. Glycation, oxidation, and glyoxidation in the pathogenesis of atherosclerosis in diabetes. Modern Medicine 1993; 61 (Suppl 2): 4-8.
36. Bucala R et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-6438.
37. Vlassara H. Recent progress on the biological and clinical significance of advanced glycosylation end products. J Lab Clin Med 1994; 124 (1): 19-30.
38. Garcia Frade LJ et al. Diabetes mellitus as an hypercoaguable state: its relationships with fibrin fragments and vascular damage. Thromb Res 1987; 47: 533-540.
39. 1 and fasting-serum glucose in young diabetic women. Diabetes Care 1980; 3 (6): 655-658.
40. Esposito C et al. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 70: 1387-1407.
41. Ford I et al. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabetic Med 1991; 8: 322-329.
42. Ibbotson SH, Walmsley D, Davis JA, Grant PJ. Generation of thrombin activity in relation to factor VIII: concentrations and vascular complications in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992; 5: 863-867.
43. Vukovich TC et al. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Throm Haemost 1992; 68 (3): 253-256.
44. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72.
45. Cagliero E et al. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 1988; 82: 735-738.
46. Mirropoulos KA. Hypercoagulability and factor VII in hyperglyceridemia. Semin Thromb Hemost 1988; 14: 246-252.
47. Pasi KJ et al. Qualitative and quantitative abnormalities of von Willebrand antigen in patients with diabetes mellitus. Thromb Res 1990; 59: 581-591.
48. Vukovich TC et al. The effect of near normoglycemic control on plasma factor VIII/von Willebrand factor and fibrin degradation products in insulin-dependent diabetic patients. J Clin Endocrinol Metab 1989; 69: 84-89.
49. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273-278.
50. Carmassi F et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67: 643-654.
51. Ceriello A et al. Metabolic control may alter antithrombin III activity but not in plasma concentration in diabetes: a possible role for nonenzymatic glycosylation. Diabetes Care 1986; 9: 32-35.
52. Vukovic TC, Schernthaner G. Decreased protein C levels in patients with insulin dependent type I diabetes mellitus. Diabetes 1986; 35: 617-619.
53. Potter van Loon B et al. The cardiovascular risk factor plasminogen activator inhibitor type I is related to insulin resistance. Metabolism 1993; 42: 945-949.
54. Jakl R, Klein RL, Lopez-Vialla MF, Coldwell JA. Release of platelet plasminogen activator inhibitor in whole blood is increased in patients with type 2 diabetes. Diabetes Care 1995; 18: 1150-1155.
55. Hamsten A et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
56. Hseuh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 1992; 20: 253-235.
57. Testamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991; 87: 1643-1648.
58. Cagliero E, Roth T, Roy S, Lorenzi M. Characteristics and mechanisms of high-glucose-induced over-expression of basement membrane components in cultured human endothelial cells. Diabetes 1991; 40: 102-110.
59. Walsh MF et al. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996; 137: 2798-1803.
60. Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death. Diabetes 1985; 34: 621-627.
61. Creager MA et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228-234.
62. Andrews HE, Bruckdorker KR, Dunn RC, Jacobs M. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature (Lond) 1987; 327: 237-239.
63. Gianturco SH, Bradley WA. Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia. Semin Thromb Hemost 1988; 14: 165-169.
64. Cockcroft JR, Chowienczijk PB, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilation in patients with essential hypertension. N Engl J Med 1994; 330: 1036-1040.
65. + exchange, c-fos expression, mitogenesis in rat mesangial cells. J Clin Invest 1989; 83: 708-712.
66. Shultz PJ, DiCorleto PE, Silver BJ, Abboud HA. Mesangial cells express PDGF mRNA's and proliferate in response to PDGF. Am J Physiol 1988; 255: F674-F684.
67. O'Donnell MP et al. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 1992; 20: 651-658.
68. O'Donnell MP et al. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 91: 83-87.
69. Shultz PJ, Schorer AE, Raij L. Effects of endothelium-derived relaxing factor and nitric oxide on rat mesangial cells. Am J Physiol 1990; 258: F162-F167.
70. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
71. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-1790.
72. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel Ii) JAMA 1993; 269: 3015-3023.
73. Gotto A. Lipid lowering, regression, and coronary events. Circulation 1995; 92: 646-656.
74. Brunwald E. Cholesterol and Recurrent Events (CARE) Trial for Secondary Prevention in Patients with Average Serum Cholesterol Levels. Presented at the American College of Cardiology Conference, March 26, 1996, Orlando, FL.
75. Shephard J et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolima. N Engl J Med 1995; 333: 1301-1307.
76. Sowers JR. Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Nephrol Dial Transplant 1995; 10: (Suppl 9): 52-55.
77. Lee AF, Struthers AD. The impact of angiotensin converting enzyme inhibitors on the arterial wall. Vasc Med 1996; 1: 109-113.
78. Shah BR et al. Differential effects of renin angiotensin system blockade on atherogenesis in cholesterol fed rabbits. J Clin Invest 1993; 91: 1453-1458.
79. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991; 9: 3-15.
80. Paquet JL, Bandomin Legros M, Brunnelle G, Meyer R. Angiotensin II induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990; 8: 565-572.
81. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450-456.
82. Black MJ et al. Effects of enalapril on aortic smooth muscle cell polyploidy in the spontaneously hypertensive rat. J Hypertens 1989; 7: 997-1003.
83. Powell JS et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-188.
84. Aberg G, Ferrer P. Effects of captopril and atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 5 (5): S65-S72.
85. Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovas Pharmacol 1991; 18 (2): S110-S115.
86. Casino PR et al. The role of nitric oxide in endothelial dependent vasodilation of the hypercholesterolaemic patient. Circulation 1993; 88: 2541-2547.
87. Farhy RD, Carretero OA, Ho K-L, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin-converting enzyme inhibitors on neointima formation. Circ Res 1993; 72: 1202-10.
88. The Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 1992; 86: 100-110.
89. Swedberg K et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study (Consensus II). N Engl J Med 1992; 327: 678-684.
90. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
91. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.
92. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
93. Kober L et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.